Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Recap by typeshit. Post by Abhijit Chokshi | Investors का दोस्त on X.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Gottlieb also covers the FDA's new Rare Disease Framework Initiative and the latest on the measles outbreak in the CNBC interview.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
Loading…